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IMPORTANCE It is uncertain to what extent established cardiovascular risk factors are
associated with venous thromboembolism (VTE).
OBJECTIVE To estimate the associations of major cardiovascular risk factors with VTE, ie,
deep vein thrombosis and pulmonary embolism.
DESIGN, SETTING, AND PARTICIPANTS This study included individual participant data
mostly from essentially population-based cohort studies from the Emerging Risk Factors
Collaboration (ERFC; 731 728 participants; 75 cohorts; years of baseline surveys, February
1960 to June 2008; latest date of follow-up, December 2015) and the UK Biobank (421 537
participants; years of baseline surveys, March 2006 to September 2010; latest date of
follow-up, February 2016). Participants without cardiovascular disease at baseline were
included. Data were analyzed from June 2017 to September 2018.
EXPOSURES A panel of several established cardiovascular risk factors.
MAIN OUTCOMES ANDMEASURES Hazard ratios (HRs) per 1-SD higher usual risk factor levels (or
presence/absence). Incident fatal outcomes in ERFC (VTE, 1041; coronary heart disease [CHD],
25 131) and incident fatal/nonfatal outcomes in UKBiobank (VTE, 2321; CHD, 3385). Hazard
ratios were adjusted for age, sex, smoking status, diabetes, and bodymass index (BMI).
RESULTS Of the 731 728participants from theERFC, 403396 (55.1%)were female, and themean
(SD) age at the timeof the surveywas51.9 (9.0) years; of the421 537participants fromtheUK
Biobank, 233699 (55.4%)were female, and themean (SD) age at the timeof the surveywas 56.4
(8.1) years. Risk factors forVTE includedolder age (ERFC:HRperdecade, 2.67; 95%CI, 2.45-2.91;
UKBiobank:HR, 1.81; 95%CI, 1.71-1.92), current smoking (ERFC:HR, 1.38;95%CI, 1.20-1.58;UK
Biobank:HR,1.23;95%CI,1.08-1.40),andBMI(ERFC:HRper1-SDhigherBMI,1.43;95%CI,1.35-1.50;
UKBiobank:HR, 1.37; 95%CI, 1.32-1.41). For these factors, therewere similarHRs for pulmonary
embolismanddeepveinthrombosis inUKBiobank(exceptadipositywasmorestronglyassociated
withpulmonaryembolism)andsimilarHRsforunprovokedvsprovokedVTE.Apart fromadiposity,
these risk factorswere less strongly associatedwithVTE thanCHD.Therewere inconsistent
associationsofVTEswithdiabetes andbloodpressure acrossERFCandUKBiobank, and there
was limited ability to study lipid and inflammationmarkers.
CONCLUSIONS AND RELEVANCE Older age, smoking, and adiposity were consistently
associated with higher VTE risk.
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V enous thromboembolism(VTE), consistingofdeepveinthrombosis (DVT)orpulmonaryembolism(PE), is ama-jor clinical burden. Globally, there are about 10million
cases every year, and it is the third leading vascular disease af-
ter myocardial infarction and stroke.1 Pulmonary embolism is
amanifestationofVTEand is responsible formostVTEdeaths.2
In recent years, efforts to prevent VTE have broadened from
focusingmainly onhospital-based risk factors (eg, recent prior
surgery, cancer, and congestive heart failure) toward adoption
of heart-healthy lifestyles.3 This perspective has challenged
traditional views of venous and arterial thrombosis as distinct
pathologies, encouraging prevention strategies that concomi-
tantly address VTE and arterial thrombosis.2,4 However, there
is uncertainty about the extent to which venous and arterial
thrombosis share cardiovascular risk factors, as studies have
reported conflicting findings.5-15 Interpretation has been com-
plicated by the use of retrospective case-control designs, lim-
ited statistical power, and/or inability to compare VTE and
arterial disease outcomes within the same cohorts.16-26
Analyzing data frommore than 1.1 million participants in
76 prospective studies, we investigated associations of sev-
eral established cardiovascular risk factors with the inci-
denceofVTEoutcomes.Weaimed toaddress2principal ques-
tions: What are the associations of major cardiovascular risk
factorswithVTEoutcomes (includingsubtypes)?Howdothese
associations compare with those for coronary heart disease
(CHD), a manifestation of arterial thrombotic disease?
Methods
Data Sources and Participant Inclusion
We analyzed data from the Emerging Risk Factors Collabora-
tion (ERFC), a consortium of prospective cohort studies with
information on a variety of risk factors, and the UK Biobank,
a single large prospective study. Both the ERFC and UK
Biobankhavebeendescribedpreviously.27,28Bothdatasources
involve a prospective cohort study design and accessible
individual participant data, enabling standardized and de-
tailed analyses using a common protocol, including defini-
tions forVTEandCHDoutcomes.However,weconductedpar-
allel (rather than pooled) analyses of the 2 sources because of
potentially important differences in their approaches to VTE
ascertainment, ie, the ERFC recorded only fatal VTE out-
comeswhileUKBiobank recordedboth fatal andnonfatalVTE
outcomes, most of which were nonfatal. Information about
each of the 76 studies contributing to this analysis is pro-
vided in the eAppendix in the Supplement. The study was
designed and conducted by the Emerging Risk Factors
Collaboration academic coordinating center, and it was ap-
proved by the Cambridgeshire Ethics Review Committee.
Informed consent was obtained from participants in each of
the cohorts contributing to the analysis.
Participants in the contributing studies were eligible for
inclusion in the current analysis if theymet all of the following
criteria: (1) had recorded information on several established
cardiovascular risk factors (as aminimum, informationonage,
sex, smoking status, history of diabetes, and bodymass index
[BMI]), (2) did not have a knownbaseline history of cardiovas-
culardisease (CVD;definedasCHD,otherheartdisease, stroke,
transient ischemic attack, peripheral vascular disease, or
cardiovascular surgery) or VTE (defined as DVT or PE), and
(3) had at least 1 year of follow-up data after baseline.
In the ERFC, only fatal VTE events were recorded. Ascer-
tainmentwas based ondeath certificates supplemented in 56
studies by medical records, findings on autopsy, and other
sources. In UK Biobank, fatal and nonfatal VTEs were ascer-
tained through linkage with routinely collected medical rec-
ords. We attempted to subcategorize VTEs as provoked and
unprovoked using a pragmatic approach that required infer-
ence from routine records (eAppendix in the Supplement).
Briefly, following the example of previouswork,13wedefined
VTE as provoked if, in the 90-day period preceding the VTE,
the participantwas recorded as having amalignant neoplasm
(per cancer registry data); starting or ending a hospital epi-
sode with a main diagnosis code relating to malignant neo-
plasm, heart failure, infectious disease, or trauma; or having
a hospital episode that included certain types of surgical pro-
cedures. The specific International Statistical Classification
of Diseases and Related Health Problems (ICD) codes and
Classificationof InterventionsandProcedures codes that are in-
cluded in our definition are summarized in the eAppendix in
the Supplement. All studies useddefinitions of CHDbasedon
World Health Organization (or similar) criteria. In registering
fatal outcomes, the contributing studies classified deaths
according to the primary cause (or, in its absence, the under-
lying cause) on the basis of ICD-8, ICD-9, and ICD-10 codes to
at least 3 digits or according to study-specific classification
systems. In the ERFC, baseline surveys were given between
February 1960 and June 2008, and the date of latest
follow-upwas December 2015 (median, 2014 across studies);
in the UK Biobank, baseline surveys were given between
March 2006 and September 2010, and the date of latest
follow-up was February 2016.
Statistical Analysis
For continuous risk factors,we calculated hazard ratios (HRs)
per 1-SD higher usual risk factor level. For binary risk factors,
we compared presence vs absence of the factor. Cox propor-
tional hazards regressionmodelswere adjusted for age, smok-
ing status, historyofdiabetes, andBMIandstratifiedby study,
sex, and (when appropriate) trial arm. To avoid overadjust-
ment, we did not routinely adjust for systolic blood pressure
Key Points
Question To what extent are established cardiovascular risk
factors associated with risk of venous thromboembolism (VTE)?
Findings In this analysis of individual participant data from the
Emerging Risk Factors Collaboration and the UK Biobank including
1.1 million participants, among a panel of several established
cardiovascular risk factors, older age, smoking, and greater
adiposity were consistently associated with higher VTE risk.
Meaning There is overlap in at least someof themajor population
determinants of important venous andarterial thrombotic diseases.
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or lipid measurements (which, for example, can mediate the
effects of adiposity). Similarly,wedidnot adjust forBMIwhen
analyzing other measures of adiposity (eg, waist circumfer-
ence). Participants in the UK Biobank were censored at first
nonfatal CVD event, death, or study exit, whichever occurred
first. Participants inERFCwerecensoredatdeathor studyexit.
BecausenonfatalCVDmayresult inhospitalization(whichmay,
in turn, lead to VTE outcomes), sensitivity analyses addition-
ally censored at the first nonfatal CVD event in ERFC.
To correct for regression dilution caused by variability in
levels of continuous risk factors, we regressed serial measure-
ments of risk factors obtained from up to 146749 participants
in ERFC (mean interval, 8.4 years) and up to 24235 partici-
pants in UK Biobank (mean interval, 5.2 years) on baseline
levels of the relevant characteristics. Correction for within-
person variation in risk factors was achieved by use of condi-
tional expectations of long-term average levels (termed usual
levels) of the risk factors, which were predicted from regres-
sion calibration models and used in estimation of HRs, as
described previously.29
To characterize shapes of associations, HRs calculated
within overall fifths of baseline exposure values were plotted
againstmeanusualvaluesof therelevant risk factorwithineach
fifth. We used the Plummermethod to estimate 95% CIs from
the variances that corresponded to the amount of information
underlying each group (including the reference category).30
Because a further aim of the study was to compare asso-
ciations of risk factors with VTE vs CHD outcomeswithin the
same cohorts,we defined a competing riskmodel using a rec-
ord duplication approach, allowing for simultaneous cause-
specific hazard regression to estimate cause-specific HRs for
each type of event. In ERFC, we stratified the cause-specific
regressionmodelbycohort toallowforadifferentbaselinehaz-
ard function in each study. We tested for differences in asso-
ciations with VTE vs CHD based on the interaction between
eachexposurevariable and theevent type indicator variable.31
Analyses were carried out in Stata version 13 (StataCorp).
Because of the number of statistical tests done, principal
emphasis was given to findings with a P value less than .001,
and all P values were 2-sided.
Results
Data were available for 731 728 participants from 75 ERFC co-
hortsand421537participants fromUKBiobank(Table) (eTable1
in the Supplement). The mean (SD) age at baseline was 51.9
(9.0) years inERFCand56.4 (8.1) years inUKBiobank; 403396
participants (55.1%) in the ERFC and 233699 (55.4%) in UK
Biobankwere female.Mostparticipants inERFCwereenrolled
in either Europe (369757 of 731 728 [50.5%]) orNorthAmerica
(315278 of 731 728 [43.1%]). During amedian follow-up of 15.4
years, 1041 fatal VTE events and 25 131 fatal CHD events were
recorded in theERFC. InUKBiobank,2321 fatalornonfatalVTE
events and 3385 fatal or nonfatal CHD events were recorded
during amedian follow-up of 6.1 years.
Associationsof several risk factorswithVTEwereapproxi-
mately log-linear (Figure1).Olderagewasassociatedwithhigher
risk of VTE,with an approximately 2.8-fold higher risk per de-
cade inERFCand1.8-foldhigher riskperdecade inUKBiobank
(Figure2).Comparedwithfemales,maleshadahigherriskofVTE
inUKBiobank (HR, 1.44;95%CI, 1.32-1.56), somewhat less so in
ERFC(HR, 1.17;95%CI,0.998-1.38).Current smokingwasasso-
ciatedwith VTE risk in ERFC (HR, 1.38; 95% CI, 1.20-1.58), but
somewhat less so in UK Biobank (HR, 1.23; 95% CI, 1.08-1.40).
Markersofadiposity (BMI,waist-to-hip ratio, andwaist circum-
ference)werepositivelyassociatedwithhigherVTErisk inboth
ERFC and UK Biobank. For example, HRs per 1-SD higher BMI
were 1.43 (95%CI, 1.35-1.50) inERFCand1.37 (95%CI, 1.32-1.41)
inUKBiobank. Current alcohol consumptionwas inversely as-
sociatedwithVTErisk inbothERFC(HR,0.75;95%CI,0.61-0.93)
and UK Biobank (HR, 0.82; 95% CI, 0.71-0.94). In exploratory
analyses restricted to current drinkers in UK Biobank (which
should limit theeffectsofcertainresidualbiases, suchasreverse
causality related to sick quitters32), we found that the inverse
associationbetweenamountofalcohol consumedandVTErisk
persisted (eFigure 1 in the Supplement).
By contrast, for some other risk factors we studied, we
notedpotentially directionally discordant associations across
ERFCandUKBiobank.For example, 1-SDhigher systolic blood
pressurewasnotassociatedwith riskofVTE inERFC (HR, 1.07;
95%CI,0.95-1.19)butwas inverselyassociatedwith riskofVTE
inUKBiobank (HR,0.83; 95%CI, 0.77-0.90). Conversely, 1-SD
higherdiastolic bloodpressurewasassociatedwithhigher risk
of VTE in ERFC (HR, 1.26; 95% CI, 1.11-1.42) but was not asso-
ciatedwith risk ofVTE inUKBiobank (HR,0.94; 95%CI, 0.87-
1.02). In ERFC, history of diabeteswas associatedwith higher
riskofVTE (HR, 1.69;95%CI, 1.33-2.16) aswas 1-SDhigher fast-
ing baseline glucose concentration (HR, 1.27; 95% CI, 1.08-
1.48), while in UK Biobank, history of diabetes was inversely
associated with risk of VTE (HR, 0.83; 95% CI, 0.69-0.99). To
investigate whether these discordant associations chiefly
reflectedthedifferentVTEoutcomesrecordedacrossERFCand
UK Biobank, we restricted analysis to the UK Biobank (which
had recorded both fatal and nonfatal VTE outcomes). In UK
Biobank–specific analyses, we found a similar pattern of dif-
ference of HRs for fatal vs nonfatal VTEs with blood pressure
and diabetes to that observed in our comparison across ERFC
and UK Biobank (eFigure 2 in the Supplement). This result
suggests that blood pressure and diabetesmay have differing
associations with fatal vs nonfatal VTEs.
At the timeofouranalysis,dataonplasmabiomarkerswere
available in the ERFC but not in UK Biobank (Figure 2). In the
ERFC,apolipoproteinB,apolipoproteinA,andlipoprotein(a) lev-
els each showed suggestively inverse associations with risk of
VTE, whereas triglyceride, non–high-density lipoprotein cho-
lesterol, and high-density lipoprotein cholesterol levels each
showednoassociations.Fastingglucose,C-reactiveprotein,and
fibrinogen levelswere each associatedwithhigher risk ofVTE.
In analyses comparing PE with DVT, higher BMI and
higher waist circumference had stronger associations with
PE than DVT (Figure 3). Further analyses that subcategorized
VTE outcomes as provoked vs unprovoked in UK Biobank
did not reveal major differences in the associations of most
CVD risk factors, with the exceptions of older age and male
sex (Figure 4).
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InanalysescomparingVTEwithCHDoutcomes,associations
werestrongerforCHDinbothERFCandUKBiobankformostrisk
factors, includingage,malesex, currentsmokingstatus,history
ofdiabetes,highersystolicanddiastolicbloodpressure,andpro-
atherogenic lipid levels (eFigures3and4 in theSupplement). In
contrast, higher BMI and waist circumference had somewhat
strongerassociationswithVTEcomparedwithCHD,whereascir-
culating inflammatorymarkerswere associatedwithboth con-
ditionstoabroadlysimilarextent(eFigures3and4intheSupple-
ment).Findingswerebroadlysimilar insensitivityanalyses that
didnotadjustforBMI(eTable2intheSupplement),excludedpar-
ticipantswith history of cancer diagnosis at baseline (eFigure 5
intheSupplement), censoredfor firstCVDevents inERFC(eFig-
ure6intheSupplement),andusedbaseline levelsof riskfactors,
except for the expected decrease in themagnitudes of associa-
tionwhennotcorrectingforwithin-personvariability inthecon-
tinuous variables (eFigures 7-9 in the Supplement).
Discussion
In this analysis of individual-level data on several estab-
lished cardiovascular risk factors from more than 1.1 million
participants in 76 cohorts, we found that older age, smoking,
Table. Summary of Baseline Characteristics and Outcomes Recorded
Characteristic
ERFC UK Biobanka
No. of
Cohorts No. Measure No. Measure
Demographic and lifestyle factors, No. (%)
Age at baseline survey, mean (SD), y 75 731 728 51.9 (9.0) 421 537 56.4 (8.1)
Male 70 731 728 328 332 (44.9) 421 537 187 838 (44.6)
Current smoker 75 731 728 222 016 (30.3) 421 537 43 847 (10.4)
History of diabetes 74 731 728 25 982 (3.6) 421 537 17 622 (4.2)
Current alcohol drinker 58 386 831 271 499 (70.2) 421 197 389 507 (92.5)
Anthropometric and physical markers,
mean (SD)
Systolic blood pressure, mm Hg 73 566 724 131 (19) 421 179 137 (19)
Diastolic blood pressure, mm Hg 72 565 895 80.0 (10.9) 421 181 82.2 (10.1)
Body mass indexb 75 731 728 25.4 (4.2) 421 537 27.2 (4.7)
Waist-to-hip ratio 34 264 787 0.85 (0.08) 421 440 0.87 (0.09)
Waist circumference, cm 36 265 465 87.6 (12.5) 421 464 89.6 (13.2)
Lipid-related markers, mean (SD)
Total cholesterol levels, mg/dL 68 455 177 222.0 (43.6) NA NA
Non-HDL cholesterol levels, mg/dL 57 311 888 171.0 (44.8) NA NA
HDL cholesterol levels, mg/dL 57 312 207 52.9 (14.7) NA NA
Log triglyceride levels, mg/dLc 56 322 096 4.79 (0.53) NA NA
Apolipoprotein B levels, mg/dL 20 80 712 103 (29) NA NA
Apolipoprotein A1 levels, mg/dL 20 84 483 137 (33) NA NA
Log Lp(a) levels, mg/dLd 18 66 382 2.20 (1.20) NA NA
Metabolic and inflammatory markers,
mean (SD)
Fasting glucose levels, mg/dL 33 130 322 88.5 (24.3) NA NA
Log CRP levels, mg/Le 28 70 855 0.46 (1.07) NA NA
Fibrinogen levels, mg/dL 29 115 002 241.2 (68.7) NA NA
Albumin levels, g/dL 25 115 309 4.29 (0.39) NA NA
Study period, median
(5th centile-95th centile)f
Baseline survey year 75 731 728 1986
(1971-2000)
421 537 2009
(2007-2010)
Latest follow-up year 75 731 728 2004
(1989-2011)
421 537 2016
(2016-2016)
Outcomes, No.
Time to event or censoring, median
(5th centile-95th centile), y
75 731 728 15.4
(5.5-32.0)
421 537 6.1
(4.8-7.5)
Total follow up, person-years in millions 75 731 728 12.807 421 537 2.566
Non-fatal MI NAg NA NA 421 537 2808
Fatal CHD 75 731 728 25 131 421 537 577
VTE 75 731 728 1041 421 537 2321
Nonfatal VTE NAg NA NA 421 537 2234
Fatal VTE 75 731 728 1041 421 537 87
Pulmonary embolism 75 731 728 855 421 537 1273
Deep venous thromboembolism 75 731 728 186 421 537 1048
Unprovoked VTE NA NA NA 421 537 1465
Provoked VTE NA NA NA 421 537 856
Abbreviations: CHD, coronary heart
disease; CRP, C-reactive protein;
ERFC, Emerging Risk Factors
Collaboration; HDL, high-density
lipoprotein; Lp(a), lipoprotein(a);
MI, myocardial infarction; NA, not
applicable; PE, pulmonary embolism;
VTE, venous thromboembolism.
SI conversion factor: To convert
cholesterol to millimoles per liter,
multiply by 0.0259; triglycerides to
millimoles per liter, multiply by
0.0113; apolipoprotein to grams per
liter, multiply by 0.01; Lp(a) to
micromoles per liter, multiply by
0.0357; fasting glucose to
micromoles per liter, multiply by
0.0555; CRP to nanomoles per liter,
multiply by 9.524; fibrinogen to
grams per liter, multiply by 0.01; and
albumin to grams per liter, multiply
by 10.
a At the time of these analyses, data
on plasma biomarkers were not
available in UK Biobank.
bBodymass index calculated as
weight in kilograms divided by
height in meters squared.
c Median (interquartile range)
triglyceride level was
117 (82-170) mg/dL.
dMedian (interquartile range) Lp(a)
level was 9 (4-25) mg/dL.
e Median (interquartile range) CRP
level was 1.48 (0.72-3.15) mg/dL.
f Follow-up and outcome summaries
among participants with complete
data on age, sex, smoking status,
history of diabetes, and body
mass index.
gMost of the studies in ERFC did not
ascertain nonfatal VTE outcomes;
hence, analyses in ERFCwere
restricted to comparison of fatal
CHD outcomes only.
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and higher levels of adiposity were clearly associated with
higher risk of VTE. These findings suggest that there is over-
lap in at least somemajor population determinants of impor-
tant venous and arterial thrombotic diseases.
Our study characterized dose-response associations be-
tweenseveral clinicalmeasuresof adiposity (eg,waist circum-
ference and BMI) and VTE risk and showed no evidence of a
threshold below which leaner body habitus stopped being
associatedwith lowerVTErisk.Theassociationofobesitywith
VTE is supportedbypreviousmendelian randomization stud-
ies of genetic variants associated with increased adiposity,
which are also associatedwith increased risk ofVTE.33,34 Fur-
thermore, we found that associations of BMI and waist cir-
cumferenceweresomewhatstrongerwithPEvsDVTandabout
twice as strong with VTE vs CHD. These data suggest that
efforts to combat the entire spectrum of obesity and over-
weight should yield important benefits for VTE prevention.
As regards risk behaviors, our study confirmed theknown
association of current smokingwith risk of VTE.9,13 This asso-
ciationwas similar inmagnitude forPEandDVToutcomesbut
weaker than that observed for CHD. Previous studies have
suggested thatmuch of the excess risk of VTE in smokerswas
because of increased hospitalization for smoking-related
diseases, includingcancer.35,36However, inouranalysis, smok-
ing was similarly associated with both provoked and unpro-
voked VTE; furthermore, HRs did not change appreciably
after exclusion of participants with history of cancer diagno-
sis at baseline. We also noted a pattern of association
Figure 1. Hazard Ratios (HRs) for Venous Thromboembolism (VTE) by 10-Year Age Groups and Fifths of Continuous Factors
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All comparisons were adjusted for age, sex, smoking status, history of diabetes,
and usual bodymass index (BMI; calculated as weight in kilograms divided by
height in meters squared) (waist-to-hip ratio and waist circumference were not
adjusted for usual BMI). The reference category is age 50 to 59 years for age
and is the bottom fifth for all other continuous variables. Associations involve
Emerging Risk Factors Collaboration (ERFC) data for fatal VTE and UK Biobank
data for VTE. Data on cholesterol and triglyceride levels were unavailable in UK
Biobank at the time of analysis. Most UK Biobank participants were aged
between 40 and 69 years at baseline. The dotted line indicates the reference
value. HDL indicates high-density lipoprotein.
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between alcohol consumption and VTE similar to that re-
ported in previous studies of alcohol consumption and
nonfatalmyocardial infarction.32,37,38 (Bycontrast, alcoholcon-
sumptionhaspreviously beenpositively associatedwith risks
of fatal coronary disease, stroke, and heart failure.) Although
previous studies have reported that moderate alcohol con-
sumption is associated with lower levels of hemostatic fac-
tors (eg, fibrinogen, factorVII, andvonWillebrand factor),39,40
further studies are needed to determine whether moderate
alcohol consumption has a causal role in VTE.
Our study identified potentially inverse associations of
proatherogenic lipid levels with VTE. For example, apolipo-
Figure 2. Hazard Ratios (HRs) for Venous Thromboembolism (VTE) for Established Cardiovascular Risk Factors
HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Association
P Value
Age (per decade)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.81 (1.71-1.92)
2.67 (2.45-2.91)
<.001
<.001
Sex (male vs female)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.44 (1.32-1.56)
1.17 (0.998-1.38)
<.001
.053
Smoking (current vs other)
UK Biobank
ERFC
421 537
731 728
2321
1041
1.23 (1.08-1.40)
1.38 (1.20-1.58)
.002
<.001
Diabetes (yes vs no)
UK Biobank
ERFC
421 537
731 728
2321
1041
0.83 (0.69-0.99)
1.69 (1.33-2.16)
.04
<.001
Alcohol consumption (current vs other)
UK Biobank
ERFC
421 197
386 831
2319
564
0.82 (0.71-0.94)
0.75 (0.61-0.93)
.006
.01
Systolic blood pressure
UK Biobank
ERFC
421 179
566 724
2315
887
0.83 (0.77-0.90)
1.07 (0.95-1.19)
<.001
.28
Diastolic blood pressure
UK Biobank
ERFC
421 181
565 895
2315
885
0.94 (0.87-1.02)
1.26 (1.11-1.42)
.15
<.001
BMI
UK Biobank
ERFC
421 537
731 728
2321
1041
1.37 (1.32-1.41)
1.43 (1.35-1.50)
<.001
<.001
Waist-to-hip ratio
UK Biobank
ERFC
421 440
264 787
2319
329
1.52 (1.40-1.65)
1.23 (1.05-1.45)
<.001
.01
Waist circumference
UK Biobank
ERFC
421 464
265 465
2320
333
1.60 (1.52-1.68)
1.54 (1.37-1.73)
<.001
<.001
Non-HDL cholesterol levels
ERFC 311 888 440 0.88 (0.76-1.03) .11
HDL cholesterol levels
ERFC 312 207 440 1.09 (0.94-1.26) .27
Log triglycerides levels
ERFC 322096 537 0.95 (0.81-1.11) .49
Apolipoprotein B levels
ERFC 80 712 261 0.76 (0.61-0.94) .01
Apolipoprotein A1 levels
ERFC 84 483 265 0.65 (0.47-0.88) .006
Log Lp(a)
ERFC 66 382 210 0.83 (0.71-0.98) .03
Fasting glucose levels
ERFC 130 322 323 1.27 (1.08-1.48) .003
Log CRP
ERFC 70 855 231 1.71 (1.33-2.20) <.001
Fibrinogen levels
ERFC 115 002 223 1.37 (1.11-1.68) .003
Albumin levels
ERFC 115 309 367 0.75 (0.56-1.02) .07
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve
Emerging Risk Factors Collaboration
(ERFC) data for fatal VTE and UK
Biobank data for VTE. CRP indicates
C-reactive protein; HDL, high-density
lipoprotein; Lp(a), lipoprotein(a).
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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protein B and lipoprotein(a) levels were each associated with
lower risk of VTE, a finding that awaits further elucidation.41
Proinflammatory soluble biomarkers (eg, C-reactive protein)
were positively associated with VTE, a finding consistent
with the associations we observed for CHD outcomes.
Although previous mendelian randomization studies sug-
gest that CRP and fibrinogen levels are unlikely to be direct
causal factors in CHD,42,43 such genetic epidemiological data
are sparser in relation to VTE.
It is not clear why our study found inconsistent associa-
tions of blood pressure and history of diabetes with VTE out-
comes across UK Biobank and the ERFC. One potential
explanation is that these data sources recorded mostly dif-
fering types of VTE outcomes, ie, UK Biobank involved
mostly nonfatal outcomes whereas ERFC involved only fatal
outcomes. Our exploratory analysis of UK Biobank data was
consistent with this explanation, as it found differing results
with blood pressure and diabetes for fatal VTE vs nonfatal
VTE similar to those observed in comparisons across UK
Biobank and the ERFC. However, future studies with more
detailed clinical information will be needed to understand
these possible differences with greater confidence.
Strengths and Limitations
Our study had major strengths. It avoided the limitations
of retrospective case-control study designs by analyzing
prospective cohort data on more than 1.1 mil l ion
participants without CVD at baseline. Access to individual
participant data avoided the limitations of literature-based
meta-analyses. It also enabled a common approach
to adjustment for potential confounding factors, time-to-
event analyses, correction for regression dilution bias,
and head-to-head comparisons of VTE and CHD. We
explored idiopathic VTE vs VTE provoked by established
risk factors (such as cancer or prolonged immobility),
albeit using pragmatic record-based definitions.44
The generalizability of our results was enhanced by
inclusion of data from 75 prospective studies in ERFC
recruited from 1960 through 2008 in 18 different
countries. To enhance power and evaluate the relevance
of findings to the contemporary situation, we included
data from UK Biobank, which recruited participants from
2006 to 2010.
Our study also had limitations. We did not routinely
have information in ERFC data on non-CVD risk factors
Figure 3. Hazard Ratios (HRs) for Pulmonary Embolism (PE) vs Deep Vein Thrombosis (DVT)
for Established Cardiovascular Risk Factors in UK Biobank
HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Difference
P Value
Age (per decade)
PE
DVT
421 537
421 537
1273
1048
1.91 (1.76-2.06)
1.70 (1.57-1.85)
.051
Sex (male vs female)
PE
DVT
421 537
421 537
1273
1048
1.37 (1.23-1.54)
1.52 (1.34-1.72)
.24
Smoking (current vs other)
PE
DVT
421 537
421 537
1273
1048
1.29 (1.09-1.53)
1.16 (0.95-1.40)
.40
Diabetes (yes vs no)
PE
DVT
421 537
421 537
1273
1048
0.74 (0.57-0.95)
0.94 (0.72-1.23)
.20
Alcohol consumption (current vs other)
PE
DVT
421 197
421 197
1272
1047
0.90 (0.74-1.10)
0.73 (0.60-0.90)
.15
Systolic blood pressure
PE
DVT
421 179
421 179
1268
1047
0.78 (0.70-0.86)
0.91 (0.81-1.02)
.046
Diastolic blood pressure
PE
DVT
421 181
421 181
1268
1047
0.96 (0.86-1.07)
0.92 (0.81-1.04)
.60
BMI
PE
DVT
421 537
421 537
1273
1048
1.44 (1.38-1.50)
1.28 (1.21-1.35)
.001
Waist-to-hip ratio
PE
DVT
421 440
421 440
1272
1047
1.67 (1.50-1.85)
1.35 (1.20-1.53)
.01
Waist circumference
PE
DVT
421 464
421 464
1273
1047
1.74 (1.63-1.86)
1.43 (1.33-1.54)
<.001
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve UK
Biobank data only.
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
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for VTE (eg, oral contraception use) or medication use (eg,
anticoagulants). Misclassification of disease outcomes
could have arisen from inaccuracies in hospital discharge
records and death certificates, diluting the strength of the
observed associations.45-47 However, 2 observations argue
against major disease misclassification in our study.
First, we observed associations of measures of adiposity
with VTE risk similar in size to those previously reported in
much smaller studies based on detailed validation
of VTE events.6 Second, we observed directionally opposite
associations of proatherogenic lipid levels with VTE
and CHD outcomes despite the 2 conditions having similar
clinical presentations.
Conclusions
Amongapanelofseveralestablishedcardiovascular risk factors,
older age, smoking, and adipositywere consistently associated
with higher VTE risk. There is overlap in at least some of the
majorpopulationdeterminantsof importantvenousandarterial
thrombotic diseases.
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HR (95% CI) per 1-SD Higher
or Contrasta
1 2 40.5
Risk Factor No.
No. of
Events
HR
(95% CI)
Difference
P Value
Age (per decade)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.68 (1.57-1.80)
2.07 (1.88-2.28)
.001
Sex (male vs female)
Unprovoked VTE
Provoked VTE
421537
421 537
1465
856
1.62 (1.46-1.79)
1.18 (1.03-1.35)
<.001
Smoking (current vs other)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.23 (1.05-1.45)
1.22 (0.98-1.51)
.91
Diabetes (yes vs no)
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
0.78 (0.62-0.99)
0.91 (0.68-1.22)
.44
Alcohol consumption (current vs other)
Unprovoked VTE
Provoked VTE
421 197
421 197
1465
854
0.83 (0.69-0.99)
0.81 (0.64-1.02)
.89
Systolic blood pressure
Unprovoked VTE
Provoked VTE
421 179
421 179
1460
855
0.86 (0.78-0.95)
0.79 (0.69-0.90)
.28
Diastolic blood pressure
Unprovoked VTE
Provoked VTE
421 181
421 181
1460
855
1.01 (0.91-1.12)
0.83 (0.73-0.95)
.02
BMI
Unprovoked VTE
Provoked VTE
421 537
421 537
1465
856
1.40 (1.34-1.46)
1.31 (1.24-1.39)
.08
Waist-to-hip ratio
Unprovoked VTE
Provoked VTE
421 440
421 440
1464
855
1.58 (1.43-1.75)
1.42 (1.24-1.63)
.21
Waist circumference
Unprovoked VTE
Provoked VTE
421 464
421 464
1465
855
1.67 (1.58-1.78)
1.47 (1.35-1.60)
.01
All comparisons were adjusted for
age, sex, smoking status, history of
diabetes, and usual bodymass index
(BMI) (waist-to-hip ratio and waist
circumference were not adjusted for
usual BMI). Associations involve UK
Biobank data only.
a Hazard ratios are presented per 1-SD
higher usual risk factor level unless
otherwise indicated.
Research Original Investigation Cardiovascular Risk Factors AssociatedWith Venous Thromboembolism
E8 JAMA Cardiology Published online January 16, 2019 (Reprinted) jamacardiology.com
Downloaded from jamanetwork.com by St George's, University of London user on 01/28/2019
Copenhagen University Hospital, Copenhagen,
Denmark (Nordestgaard); Faculty of Health and
Medical Sciences, University of Copenhagen,
Copenhagen, Denmark (Nordestgaard);
Copenhagen City Heart Study, Frederiksberg
Hospital, Copenhagen University Hospital,
Copenhagen, Denmark (Nordestgaard); Osaka
University, Osaka, Japan (Kitamura); University
Medical Center Groningen, University of Groningen,
Groningen, the Netherlands (Mahmoodi,
Kromhout); St George’s, University of London,
London, United Kingdom (Whincup); National
Institute for Health andWelfare, Helsinki, Finland
(Salomaa); Ludwig Maximilian University of Munich,
Munich, Germany (Meisinger, Nagel); Helmholtz
ZentrumMünchen, German Research Center for
Environmental Health, Neuherberg, Germany
(Meisinger); Deutsches HerzzentrumMünchen,
Technische Universität München, Munich, Germany
(Koenig); German Centre for Cardiovascular
Research (DZHK), partner site Munich Heart
Alliance, Munich, Germany (Koenig); Department of
Internal Medicine II–Cardiology, University of Ulm
Medical Center, Ulm, Germany (Koenig); Erasmus
University Medical Center, Erasmus University,
Rotterdam, the Netherlands (Kavousi); University
of Greifswald, Greifswald, Germany (Völzke,
Sundström); UCLMedical School, University
College London, London, United Kingdom
(J. A. Cooper); Kyushu University, Fukuoka, Japan
(Ninomiya); University of Padova, Padua, Italy
(Casiglia); University of Hawaii, Honolulu
(Rodriguez); Population Health Science, Bristol
Medical School, University of Bristol, Bristol, United
Kingdom (Ben-Shlomo, Gallacher, Lawlor); Institute
of Nutraceuticals and Functional Foods, Université
Laval, Quebec, Quebec, Canada (Després); The
University of New SouthWales, Sydney, New South
Wales, Australia (Simons); University of California,
San Diego (Barrett-Connor); University of
Gothenburg, Gothenburg, Sweden (Björkelund,
Rosengren); Department of Internal Medicine,
Bruneck Hospital, Bruneck, Italy (Notdurfter);
University of Edinburgh, Edinburgh, United
Kingdom (Price); Medical University of South
Carolina, Charleston (Sutherland); Institute of
Public Health and Clinical Nutrition, University of
Eastern Finland, Kuopio, Finland (Kauhanen); VU
University Medical Center Amsterdam, Amsterdam,
the Netherlands (Beulens); Julius Center for Health
Sciences and Primary Care, University Medical
Center Utrecht, Utrecht University, Utrecht, the
Netherlands (Beulens, van der Schouw,
Verschuren); Tel Aviv University, Tel Aviv, Israel
(Dankner); MRC Lifecourse Epidemiology Unit,
University of Southampton, Southampton, United
Kingdom (C. Cooper); National Institute of Health
(ISS), Rome, Italy (Giampaoli); Center of Health
Equity, Diversity and Inclusion, University of
Washington School of Medicine, Seattle (Deen);
Clinical Research and Clinical Trials Unit, Plataforma
de Innovación en Tecnologías Médicas y Sanitarias,
Madrid, Spain (Gómez de la Cámara); University of
Pittsburgh Graduate School of Public Health,
Pittsburgh, Pennsylvania (Kuller); Portland State
University, Portland, Oregon (Crespo); US Centers
for Disease Control and Prevention, Atlanta,
Georgia (Albertorio-Diaz); Monash University,
Melbourne, Victoria, Australia (Atkins); Department
of Epidemiology and Public Health, University
College London, London, United Kingdom
(Brunner, Shipley); Norwegian Institute of Public
Health, Oslo, Norway (Njølstad, Selmer); MRC
Integrative Epidemiology Unit at the University of
Bristol, Bristol, United Kingdom (Lawlor); CUNY
School of Medicine, City University of New York,
New York (Trevisan); Centre for Nutrition,
Prevention and Health Services, National Institute
for Public Health and the Environment (RIVM),
Bilthoven, the Netherlands (Verschuren); Feinberg
School of Medicine, Northwestern University,
Chicago, Illinois (Greenland); Albert Einstein
College of Medicine, New York, New York
(Wassertheil-Smoller); Institute of Cardiovascular
andMedical Sciences, University of Glasgow,
Glasgow, United Kingdom (Lowe).
Author Contributions:Drs Kaptoge and
Di Angelantonio had full access to all of the data in
the study and take responsibility for the integrity of
the data and the accuracy of the data analysis. Drs
Gregson, Kaptoge, Danesh, Di Angelantonio, and
Meade contributed equally.
Study concept and design: Gregson, Pennells,
Rodriguez, Kromhout, Deen, Svensson, Trevisan,
Wood, Danesh, Di Angelantonio, Meade.
Acquisition, analysis, or interpretation of data:
Gregson, Kaptoge, Bolton, Pennells, Willeit,
Burgess, Bell, Sweeting, Rimm, Kabrhel, Zöller,
Assmann, Gudnason, Folsom, Arndt, Fletcher,
Norman, Nordestgaard, Mahmoodi, Whincup,
Knuiman, Salomaa, Meisinger, Koenig, Kavousi,
Henry, J. Cooper, Ninomiya, Casiglia, Rodriguez,
Ben-Shlomo, Després, Simons, Barrett-Connor,
Björkelund, Notdurfter, Price, Sutherland,
Sundstrom, Kauhanen, Gallacher, Beulens, Dankner,
C. Cooper, Giampaoli, Gómez de la Cámara, Kuller,
Rosengren, Nagel, Brenner, Albertorio-Diaz, Atkins,
Shipley, Njølstad, Lawlor, van der Schouw, Selmer,
Trevisan, Verschuren, Greenland,
Wassertheil-Smoller, Lowe, Butterworth,
Thompson, Danesh, Di Angelantonio.
Drafting of the manuscript: Gregson, Bolton,
Notdurfter, C. Cooper, Deen, Danesh,
Di Angelantonio, Meade.
Critical revision of the manuscript for important
intellectual content: Kaptoge, Bolton, Pennells,
Willeit, Burgess, Bell, Sweeting, Rimm, Kabrhel,
Zöller, Assmann, Gudnason, Folsom, Arndt,
Fletcher, Norman, Nordestgaard, Mahmoodi,
Whincup, Knuiman, Salomaa, Meisinger, Koenig,
Kavousi, Henry, J. Cooper, Ninomiya, Casiglia,
Rodriguez, Ben-Shlomo, Després, Simons,
Barrett-Connor, Björkelund, Kromhout, Price,
Sutherland, Sundstrom, Kauhanen, Gallacher,
Beulens, Dankner, C. Cooper, Giampaoli, Deen,
Gómez de la Cámara, Kuller, Rosengren, Svensson,
Nagel, Brenner, Albertorio-Diaz, Atkins, Shipley,
Njølstad, Lawlor, van der Schouw, Selmer, Trevisan,
Verschuren, Greenland, Wassertheil-Smoller, Lowe,
Wood, Butterworth, Thompson, Danesh,
Di Angelantonio, Meade.
Statistical analysis: Gregson, Kaptoge, Bolton,
Pennells, Burgess, Sweeting, Sutherland, C. Cooper,
Albertorio-Diaz, Lawlor, Wood, Thompson.
Obtained funding: Nordestgaard, Henry, Casiglia,
Rodriguez, Simons, Kromhout, Sutherland,
Gallacher, Rosengren, Lawlor, Wassertheil-Smoller,
Danesh, Di Angelantonio.
Administrative, technical, or material support:
Bolton, Bell, Kabrhel, Zöller, Fletcher, Whincup,
Salomaa, Casiglia, Rodriguez, Simons, Björkelund,
Notdurfter, Kromhout, Sutherland, Kauhanen,
Beulens, Dankner, Kuller, Svensson, Nagel, Atkins,
Trevisan, Verschuren, Lowe, Danesh.
Study supervision: Kaptoge, Willeit, Rimm, Kabrhel,
Gudnason, Salomaa, Koenig, Kavousi, Casiglia,
Rodriguez, Simons, Kromhout, Kauhanen,
Svensson, Trevisan, Butterworth, Danesh, Meade.
Conflict of Interest Disclosures:Dr Gregson has
received grants from AstraZeneca and BioSensors
as well as personal fees from BioSensors, Edwards
Lifesciences, andMvRX. Dr Kaptoge has received
grants from the British Heart Foundation and the
UKMedical Research Council paid to the
Department of Public Health and Primary Care of
the University of Cambridge. Dr Kabrhel has
received grant HL116854 from the National Heart,
Lung, and Blood Institute as well as grants from
Diagnostica Stago, Janssen Pharmaceuticals, and
Siemens Healthcare Diagnostics. Dr Salomaa has
received personal fees fromNovo Nordisk. Dr
Koenig has received grants and nonfinancial
support from Abbott, Beckmann, Roche
Diagnostics, and Singulex as well as personal fees
from AstraZeneca, Novartis, Pfizer, TheMedicines
Company, GlaxoSmithKline, DalCor, Kowa, and
Amgen for consulting and from AstraZeneca,
Sanofi, and Berlin-Chernie for lectures. Dr Lawlor
has received grants from the UKMedical Research
Council, UK Economic and Social Science Research
Council, British Heart Foundation, Diabetes UK,
European Research Council, and National Institute
for Health as well as funds in kind fromMedtronic
and Roche Diagnostics paid to the University of
Bristol. Dr Butterworth has received grants from
AstraZeneca, Biogen, Merck, Novartis, and Pfizer.
Dr Thompson has received grants from British
Heart Foundation and the UKMedical Research
Council. No other disclosures were reported.
Funding/Support: This research has been conducted
using theUKBiobank resourceunderApplication
Number 26865. Thisworkwas supportedby
underpinninggrants fromtheUKMedical Research
Council(grantG0800270),theBritishHeartFoundation
(grant SP/09/002), theBritishHeart Foundation
CambridgeCardiovascular Centreof Excellence,UK
National Institute forHealthResearchCambridge
BiomedicalResearchCentre,EuropeanResearchCouncil
(grant268834),theEuropeanCommissionFramework
Programme7 (grantHEALTH-F2-2012-279233), and
HealthDataResearchUK.DrDaneshholdsaBritishHeart
FoundationPersonal Chair andaNational Institute for
HealthResearchSenior InvestigatorAward.
Role of the Funder/Sponsor: The funders had
no role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
Group Information: Investigators of the Emerging
Risk Factors Collaboration include the following:
Atherosclerosis Risk in Communities Study:Wayne
Rosamond, PhD; Eric Whitsel, PhD; andMary
Cushman, BSc (University of North Carolina, Chapel
Hill); Australian Diabetes Study: Elizabeth L. M. Barr,
PhD; Jonathan E. Shaw, MD; and Paul Z. Zimmet,
MD (Baker Heart and Diabetes Institute,
Melbourne, Victoria, Australia); Busselton Health
Study:Matthew Knuiman, PhD (The University of
Western Australia, Perth, Western Australia,
Australia); British Regional Heart Study: Peter H.
Whincup, PhD (St George’s, University of London,
London, United Kingdom); Bruneck Study: Stefan
Kiechl, MD; SiegfriedWeger, MD; and Johann
Willeit, MD (Department of Internal Medicine,
Bruneck Hospital, Italy); British Women’s Heart and
Health Study:Deborah A. Lawlor, PhD (University of
Cardiovascular Risk Factors AssociatedWith Venous Thromboembolism Original Investigation Research
jamacardiology.com (Reprinted) JAMA Cardiology Published online January 16, 2019 E9
Downloaded from jamanetwork.com by St George's, University of London user on 01/28/2019
Bristol, Bristol, United Kingdom); Antoinette
Amuzu, MA; Caroline Dale, PhD; and Juan P. Casas,
MD (University College London, London, United
Kingdom); Caerphilly Prospective Study: John
Gallacher, PhD (University of Oxford, Oxford,
United Kingdom); Cardiovascular Study in the
Elderly: Valérie Tikhonoff, MD (University of Padua,
Padua, Italy); Chicago Heart Association Detection
Project In Industry: Philip Greenland, MD
(Northwestern University, Chicago, Illinois);
Charleston Heart Study: Paul Nietert, PhD (Medical
University of South Carolina, Charleston);
Copenhagen City Heart Study: Anne
Tybjærg-Hansen, MD; Ruth Frikke-Schmidt, MD;
and Gorm B. Jensen, MD (University of
Copenhagen, Copenhagen, Denmark); Diet and Risk
of Cardiovascular Disease in Spain:David Lora
Pablos, MD; and Pilar Cancelas Navia, MD (Hospital
12 de Octubre, Madrid, Spain); Dubbo Study of the
Elderly: Leon Simons, MD (University of New South
Wales, Sydney, New SouthWales, Australia);
Edinburgh Artery Study: Stela McLachlan, PhD (The
University of Edinburgh, Edinburgh, United
Kingdom); Epidemiologische Studie zu Chancen der
Verhutung und optimierten Therapie chronischer
Erkrankungen in der alteren Bevolkerung: Ben
Schöttker, MD; Kai-Uwe Saum, PhD; and Bernd
Holleczek, PhD (German Cancer Research Center,
Heidelberg, Germany);Oslo Study, Cohort of
Norway: Inger Ariansen, PhD; Haakon E. Meyer,
MD; and Lise Lund Håheim, MD (Norwegian
Institute of Public Health, Oslo, Norway); Finrisk
Cohort 1992, Finrisk Cohort 1997: Erkki Vartiainen,
MD; Pekka Jousilahti, MD; and Kennet Harald, MD
(National Institute for Health andWelfare, Helsinki,
Finland); The Glucose Intolerance, Obesity and
Hypertension Study: Rachel Dankner, MD (Tel Aviv
University, Tel Aviv, Israel); Goteborg Study 1933,
MONICA Göteborg Study: Annika Rosengren, MD;
and Lars Wilhelmsen, MD (University of
Gothenburg, Gothenburg, Sweden); Population
Study of Women in Göteborg, Sweden: Cecilia
Björkelund, MD (University of Gothenburg,
Gothenburg, Sweden); Göttingen Risk Incidence and
Prevalence Study:Dorothea Nagel, MD (German
Cancer Research Center, Heidelberg, Germany);
Hertfordshire Cohort Study: Elaine Dennison, PhD;
Holly Syddall, PhD; and LeoWestbury, MSc
(University of Southampton, Southampton, United
Kingdom);Health in Men Study: Leon Flicker, PhD;
Graeme J. Hankey, MD (University of Western
Australia, Perth, Western Australia, Australia); and
Jonathan Golledge, MD (James Cook University,
Townsville, Queensland, Australia);Hisayama
Study: Toshiharu Ninomiya, PhD; Yasufumi Doi,
PhD; and Yutaka Kiyohara, PhD (Kyushu University,
Fukuoka, Japan);Honolulu Heart Program: Beatriz
Rodriguez, MD (University of Hawaii, Honolulu);
Hoorn Study: Petra Elders, MD; and Coen
Stehouwer, MD (VU University Medical Center,
Amsterdam, the Netherlands);Health Professionals
Follow-up Study: Christopher Kabrhel, MD
(Massachusetts General Hospital, Boston); and
Majken Jensen, PhD (Harvard T. H. Chan School of
Public Health, Boston, Massachusetts); Ikawa,
Kyowa, and Noichi Study: Akihiko Kitamura, MD
(TokyoMetropolitan Institute of Gerontology,
Tokyo, Japan); Hiroyasu Iso, MD (Osaka University
Graduate School of Medicine, Suita, Japan); and
Kazumasa Yamagishi, MD (University of Tsukuba,
Tsukuba, Japan);North Karelia Project: Veikko
Salomaa, MD (National Institute for Health and
Welfare, Helsinki, Finland); Kuopio Ischaemic Heart
Disease Study: Kurl Sudhir, MD; Tomi-Pekka
Tuomainen, PhD; and Jukka T. Salonen, MD
(University of Eastern Finland, Keupio, Finland);
Lower Extremity Arterial Disease Event Reduction
Trial, Northwick Park Heart Study II: Jackie A.
Cooper, MBBS, (UCLMedical School, University
College London, London, United Kingdom);
Monitoring of CVD Risk Factors Project, Dutch
Monitoring Project on Risk Factors for Chronic
Diseases: JolandaM. A. Boer, PhD; and Anneke
Blokstra, PhD (National Institute for Public Health
and the Environment [RIVM], Bilthoven, the
Netherlands);Malmö Diert and Cancer
Cardiovascular Study, Malmö Preventive Project:
Olle Melander, MD; Peter M. Nilsson, MD; and
Gunnar Engström, PhD (Lund University, Lund,
Sweden); Risk Factors and Life Expectancy Pooling
Project, Risk Factors and Life Expectancy Pooling
Project:Maurizio Trevisan, MD (The City College of
New York, New York); Progetto CUORE: Luigi
Palmieri, MD; Diego Vanuzzo, MD; and Simona
Giampaoli, MD (National Health Institute of Health
[ISS], Rome, Italy);MONICA/KORA Augsburg Survey
S1, MONICA/KORA Augsburg Survey S2, MONICA/
KORA Augsburg Survey S3: Annette Peters, MD;
Barbara Thorand, PhD; andMargit Heier, PhD
(German Research Center for Environmental
Health, Neuherberg, Germany);MRC Study of Older
People: Astrid Fletcher, MD (London School of
Hygiene and Tropical Medicine, London, United
Kingdom);Multiple Risk Factor Intervention Trial 1:
Lewis H. Kuller, PhD (University of Pittsburgh
Graduate School of Public Health, Pittsburgh,
Pennsylvania); National Health and Nutrition
Examination Survey I: Juan R. Albertorio-Diaz, MA
(US Centers for Disease Control and Prevention,
Atlanta, Georgia); Nurses’ Health Study: Eric B.
Rimm, ScD; Frank B. Hu, MD; and JoAnn E. Manson,
MD (Harvard T. H. Chan School of Public Health,
Boston, Massachusetts); Prevention of Renal and
Vascular End Stage Disease Study: Karina Meijer,
MD; Ron T. Gansevoort, MD (University of
Groningen, Groningen, the Netherlands); Puerto
Rico Heart Health Program: Carlos J. Crespo, MD
(Portland State University, Portland, Oregon);
Prospective Cardiovascular Münster Study: Gerd
Assmann, MD (Assmann Foundation for
Prevention, Münster, Germany); and Helmut
Schulte, PhD (University of Münster, Münster,
Germany); Prospect EPIC Utrecht: Ivonne Sluijs, PhD
(University Medical Center Utrecht, Utrecht, the
Netherlands);Quebec Cardiovascular Study:
Bernard Cantin, PhD; Benoît Lamarche, PhD; and
Gilles R. Dagenais, MD (Université Laval, Quebec,
Quebec, Canada); Rancho Bernardo Study: Linda
McEvoy, PhD; Gail Laughlin, PhD; and Lori B.
Daniels, MD (University of California, San Diego);
Reykjavik Study: Thor Aspelund, PhD; Elías Freyr
Gudmundsson, PhD; and Bolli Thorsson, PhD
(University of Iceland, Reykjavík, Iceland); The
Rotterdam Study:Maarten J. G. Leening, PhD;
M. Arfan Ikram, MD; and Oscar H. Franco, MD
(ErasmusMedical Centre, Rotterdam, the
Netherlands); Scottish Heart Health Extended
Cohort:Hugh Tunstall-Pedoe, MD (Dundee
University, Dundee, United Kingdom); Study of
Health in Pomerani:Henry Völzke, MD; and André
Werner, MD (University of Greifswald, Greifswald,
Germany); Strong Heart Study: Richard Devereux,
MD (Weill Cornell Medicine, New York, New York);
and Stacey Jolly, MD (Cleveland Clinic, Phoenix,
Arizona); Speedwell Study: George Davey Smith,
MD (Bristol University, Bristol, United Kingdom);
Turkish Adult Risk Factor Study: Günay Can, MD
(Trakya University, Edime, Turkey); Hüsniye Yüksel,
MD (Ataşehir Florence Nightingale Hospital,
Istanbul, Turkey); and Servet Altay, MD (Trakya
University, Edime, Turkey); Tromsø Study: Inger
Njølstad, MD (The Arctic University of Norway,
Tromsø, Norway); Uppsala Longitudinal Study of
Adult Men:Martin Ingelsson, MD; and Vilmantas
Giedraitis, PhD (Uppsala University, Uppsala,
Sweden);Wuertemberg ConstructionWorkers
Cohort:Hermann Brenner, MD (German Cancer
Research Center, Heidelberg, Germany); Heiner
Claessen, PhD (German Diabetes Center,
Düsseldorf, Germany); and Dietrich Rothenbacher,
MD (University of Ulm, Ulm, Germany);Women’s
Health Initiative:Nisha I. Parikh, MD (University of
California, San Francisco); and Charles Eaton, MD
(Care New England, Pawtucket, Rhode Island);
Whitehall I Study:Martin Shipley, MSc; andMika
Kivimaki, FMedSci (University College London,
London, United Kingdom);Whitehall II Study: Eric J.
Brunner, PhD; andMartin Shipley, MSc (University
College London, London, United Kingdom); and
Zutphen Elderly Study: Edith Feskens, MD; Johanna
M. Geleijnse, MD; and Daan Kromhout, MD
(Wageningen University, Wageningen, the
Netherlands); Data Management Team: Thomas
Bolton, MSc; Sarah Spackman, MMath; and
MatthewWalker, PhD (MRC/BHF Cardiovascular
Epidemiology Unit, Department of Public Health
and Primary Care, University of Cambridge,
Cambridge, United Kingdom). Coordinating Centre:
Thomas Bolton, MSc; Stephen Burgess, PhD; Adam
S. Butterworth, PhD; Emanuele Di Angelantonio,
FRCP; Stephen Kaptoge, PhD; Lisa Pennells, PhD;
Sarah Spackman, MMath; Simon G. Thompson,
PhD; MatthewWalker, PhD; Angela M.Wood, PhD;
and John Danesh, FMedSci (principal investigator)
(MRC/BHF Cardiovascular Epidemiology Unit,
Department of Public Health and Primary Care,
University of Cambridge, Cambridge,
United Kingdom).
REFERENCES
1. Di Nisio M, van Es N, Büller HR. Deep vein
thrombosis and pulmonary embolism. Lancet.
2016;388(10063):3060-3073. doi:10.1016/S0140-
6736(16)30514-1
2. Goldhaber SZ, Bounameaux H. Pulmonary
embolism and deep vein thrombosis. Lancet. 2012;
379(9828):1835-1846. doi:10.1016/S0140-6736(11)
61904-1
3. Goldhaber SZ. Risk factors for venous
thromboembolism. J Am Coll Cardiol. 2010;56(1):
1-7. doi:10.1016/j.jacc.2010.01.057
4. Lowe GD. Common risk factors for both arterial
and venous thrombosis. Br J Haematol. 2008;140
(5):488-495. doi:10.1111/j.1365-2141.2007.06973.x
5. Abdollahi M, CushmanM, Rosendaal FR.
Obesity: risk of venous thrombosis and the
interaction with coagulation factor levels and oral
contraceptive use. Thromb Haemost. 2003;89(3):
493-498. doi:10.1055/s-0037-1613379
6. AgenoW, Becattini C, Brighton T, Selby R,
Kamphuisen PW. Cardiovascular risk factors and
venous thromboembolism: a meta-analysis.
Circulation. 2008;117(1):93-102. doi:10.1161/
CIRCULATIONAHA.107.709204
7. Bai J, Ding X, Du X, Zhao X, Wang Z, Ma Z.
Diabetes is associated with increased risk of venous
thromboembolism: a systematic review and
Research Original Investigation Cardiovascular Risk Factors AssociatedWith Venous Thromboembolism
E10 JAMA Cardiology Published online January 16, 2019 (Reprinted) jamacardiology.com
Downloaded from jamanetwork.com by St George's, University of London user on 01/28/2019
meta-analysis. Thromb Res. 2015;135(1):90-95. doi:
10.1016/j.thromres.2014.11.003
8. Bell EJ, Folsom AR, Lutsey PL, et al. Diabetes
mellitus and venous thromboembolism:
a systematic review andmeta-analysis. Diabetes
Res Clin Pract. 2016;111:10-18. doi:10.1016/j.diabres.
2015.10.019
9. Cheng Y-J, Liu Z-H, Yao F-J, et al. Current and
former smoking and risk for venous
thromboembolism: a systematic review and
meta-analysis. PLoS Med. 2013;10(9):e1001515. doi:
10.1371/journal.pmed.1001515
10. Glynn RJ, Rosner B. Comparison of risk factors
for the competing risks of coronary heart disease,
stroke, and venous thromboembolism. Am J
Epidemiol. 2005;162(10):975-982. doi:10.1093/aje/
kwi309
11. Glynn RJ, Danielson E, Fonseca FAH, et al.
A randomized trial of rosuvastatin in the prevention
of venous thromboembolism. N Engl J Med. 2009;
360(18):1851-1861. doi:10.1056/NEJMoa0900241
12. Holst AG, Jensen G, Prescott E. Risk factors for
venous thromboembolism: results from the
Copenhagen City Heart Study. Circulation. 2010;121
(17):1896-1903. doi:10.1161/CIRCULATIONAHA.109.
921460
13. Mahmoodi BK, CushmanM, Anne Næss I, et al.
Association of traditional cardiovascular risk factors
with venous thromboembolism: an individual
participant data meta-analysis of prospective
studies. Circulation. 2017;135(1):7-16. doi:10.1161/
CIRCULATIONAHA.116.024507
14. Tsai AW, CushmanM, RosamondWD, Heckbert
SR, Polak JF, Folsom AR. Cardiovascular risk factors
and venous thromboembolism incidence: the
longitudinal investigation of thromboembolism
etiology. Arch Intern Med. 2002;162(10):1182-1189.
doi:10.1001/archinte.162.10.1182
15. Wattanakit K, Lutsey PL, Bell EJ, et al.
Association between cardiovascular disease
risk factors and occurrence of venous
thromboembolism: a time-dependent analysis.
Thromb Haemost. 2012;108(3):508-515.
16. CushmanM, Tsai AW,White RH, et al. Deep vein
thrombosis and pulmonary embolism in two
cohorts: the longitudinal investigation of
thromboembolism etiology. Am JMed. 2004;117(1):
19-25. doi:10.1016/j.amjmed.2004.01.018
17. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM,
Griffin JH. High-density lipoprotein deficiency and
dyslipoproteinemia associated with venous
thrombosis inmen.Circulation. 2005;112(6):893-899.
doi:10.1161/CIRCULATIONAHA.104.521344
18. Doggen CJM, Smith NL, Lemaitre RN, Heckbert
SR, Rosendaal FR, Psaty BM. Serum lipid levels and
the risk of venous thrombosis. Arterioscler Thromb
Vasc Biol. 2004;24(10):1970-1975. doi:10.1161/01.
ATV.0000143134.87051.46
19. Hansson PO, Eriksson H,Welin L, Svärdsudd K,
Wilhelmsen L. Smoking and abdominal obesity: risk
factors for venous thromboembolism among
middle-agedmen: “the study of men born in 1913.”
Arch Intern Med. 1999;159(16):1886-1890. doi:10.
1001/archinte.159.16.1886
20. Høibraaten E, Abdelnoor M, Sandset PM.
Hormone replacement therapy with estradiol and
risk of venous thromboembolism:
a population-based case-control study. Thromb
Haemost. 1999;82(4):1218-1221.
21. Kawasaki T, Kambayashi J, Ariyoshi H, SakonM,
Suehisa E, MondenM. Hypercholesterolemia as a
risk factor for deep-vein thrombosis. Thromb Res.
1997;88(1):67-73. doi:10.1016/S0049-3848(97)
00192-8
22. Lidegaard Ø, Edström B, Kreiner S. Oral
contraceptives and venous thromboembolism:
a five-year national case-control study.Contraception.
2002;65(3):187-196. doi:10.1016/S0010-7824(01)
00307-9
23. McColl MD, Sattar N, Ellison J, et al. Lipoprotein
(a), cholesterol and triglycerides in womenwith
venous thromboembolism. Blood Coagul Fibrinolysis.
2000;11(3):225-229.
24. Prandoni P, Bilora F, Marchiori A, et al. An
association between atherosclerosis and venous
thrombosis. N Engl J Med. 2003;348(15):1435-1441.
doi:10.1056/NEJMoa022157
25. SeverinsenMT, Kristensen SR, Johnsen SP,
Dethlefsen C, Tjønneland A, Overvad K. Smoking
and venous thromboembolism: a Danish follow-up
study. J Thromb Haemost. 2009;7(8):1297-1303.
doi:10.1111/j.1538-7836.2009.03490.x
26. Gariani K, Mavrakanas T, Combescure C, Perrier
A, Marti C. Is diabetes mellitus a risk factor for
venous thromboembolism? a systematic review
andmeta-analysis of case-control and cohort
studies. Eur J Intern Med. 2016;28:52-58. doi:10.
1016/j.ejim.2015.10.001
27. Danesh J, Erqou S, Walker M, et al; Emerging
Risk Factors Collaboration. The Emerging Risk
Factors Collaboration: analysis of individual data on
lipid, inflammatory and other markers in over 1.1
million participants in 104 prospective studies of
cardiovascular diseases. Eur J Epidemiol. 2007;22
(12):839-869. doi:10.1007/s10654-007-9165-7
28. Sudlow C, Gallacher J, Allen N, et al. UK
biobank: an open access resource for identifying
the causes of a wide range of complex diseases of
middle and old age. PLoSMed. 2015;12(3):e1001779.
doi:10.1371/journal.pmed.1001779
29. Wood AM,White I, Thompson SG, Lewington
S, Danesh J; Fibrinogen Studies Collaboration.
Regression dilutionmethods for meta-analysis:
assessing long-term variability in plasma fibrinogen
among 27,247 adults in 15 prospective studies. Int J
Epidemiol. 2006;35(6):1570-1578. doi:10.1093/
ije/dyl233
30. Plummer M. Improved estimates of floating
absolute risk. Stat Med. 2004;23(1):93-104. doi:10.
1002/sim.1485
31. LunnM, McNeil D. Applying Cox regression to
competing risks. Biometrics. 1995;51(2):524-532.
doi:10.2307/2532940
32. Wood AM, Kaptoge S, Butterworth AS, et al;
Emerging Risk Factors Collaboration/EPIC-CVD/UK
Biobank Alcohol Study Group. Risk thresholds for
alcohol consumption: combined analysis of
individual-participant data for 599912 current
drinkers in 83 prospective studies. Lancet. 2018;391
(10129):1513-1523. doi:10.1016/S0140-6736(18)
30134-X
33. Klovaite J, BennM, Nordestgaard BG. Obesity
as a causal risk factor for deep venous thrombosis:
a mendelian randomization study. J Intern Med.
2015;277(5):573-584. doi:10.1111/joim.12299
34. Lindström S, Germain M, Crous-BouM, et al;
INVENT Consortium. Assessing the causal
relationship between obesity and venous
thromboembolism through amendelian
randomization study.HumGenet. 2017;136(7):897-
902. doi:10.1007/s00439-017-1811-x
35. BlondonM,Wiggins KL, McKnight B, et al. The
association of smoking with venous thrombosis in
women: a population-based, case-control study.
Thromb Haemost. 2013;109(5):891-896. doi:10.
1160/TH12-10-0732
36. EngaKF,BraekkanSK,Hansen-KroneIJ, leCessieS,
Rosendaal FR,Hansen J-B. Cigarette smoking and the
risk of venous thromboembolism: theTromsøStudy.
JThrombHaemost. 2012;10(10):2068-2074.doi:10.1111/
j.1538-7836.2012.04880.x
37. Harrington LB, Hagan KA, Mukamal KJ, et al.
Alcohol consumption and the risk of incident
pulmonary embolism in US women andmen.
J Thromb Haemost. 2018;16(9):1753-1762. doi:10.
1111/jth.14224
38. Lippi G, Mattiuzzi C, Franchini M. Alcohol
consumption and venous thromboembolism: friend
or foe? Intern Emerg Med. 2015;10(8):907-913. doi:
10.1007/s11739-015-1327-0
39. Mukamal KJ, Jadhav PP, D’Agostino RB, et al.
Alcohol consumption and hemostatic factors:
analysis of the FraminghamOffspring cohort.
Circulation. 2001;104(12):1367-1373. doi:10.1161/
hc3701.096067
40. Lee KW, Lip GY. Effects of lifestyle on
hemostasis, fibrinolysis, and platelet reactivity:
a systematic review. Arch Intern Med. 2003;163(19):
2368-2392. doi:10.1001/archinte.163.19.2368
41. Morelli VM, LijferingWM, Bos MHA, Rosendaal
FR, Cannegieter SC. Lipid levels and risk of venous
thrombosis: results from theMEGA-study. Eur J
Epidemiol. 2017;32(8):669-681. doi:10.1007/s10654-
017-0251-1
42. Wensley F, Gao P, Burgess S, et al; C Reactive
Protein Coronary Heart Disease Genetics
Collaboration (CCGC). Association between C
reactive protein and coronary heart disease:
mendelian randomisation analysis based on
individual participant data. BMJ. 2011;342:d548.
doi:10.1136/bmj.d548
43. Davey Smith G, Harbord R, Ebrahim S.
Fibrinogen, C-reactive protein and coronary heart
disease: does mendelian randomization suggest the
associations are non-causal?QJM. 2004;97(3):163-
166. doi:10.1093/qjmed/hch025
44. Lapner ST, Kearon C. Diagnosis and
management of pulmonary embolism. BMJ. 2013;
346:f757. doi:10.1136/bmj.f757
45. DismukeSE,VanderZwaagR.Accuracy and
epidemiological implicationsof thedeath certificate
diagnosis of pulmonary embolism. J ChronicDis. 1984;
37(1):67-73. doi:10.1016/0021-9681(84)90127-9
46. Miniati M, Prediletto R, Formichi B, et al.
Accuracy of clinical assessment in the diagnosis of
pulmonary embolism. Am J Respir Crit Care Med.
1999;159(3):864-871. doi:10.1164/ajrccm.159.3.
9806130
47. Stein PD, Henry JW. Prevalence of acute
pulmonary embolism among patients in a general
hospital and at autopsy. Chest. 1995;108(4):978-981.
doi:10.1378/chest.108.4.978
Cardiovascular Risk Factors AssociatedWith Venous Thromboembolism Original Investigation Research
jamacardiology.com (Reprinted) JAMA Cardiology Published online January 16, 2019 E11
Downloaded from jamanetwork.com by St George's, University of London user on 01/28/2019
